$SERA

Sera Prognostics (Nasdaq:SERA) - Stock Analysis

This Simply Wall St analysis provides a comprehensive overview of Sera Prognostics (SERA), a women's health company. It details SERA's market capitalization, current stock price, analyst price target of US$5 (indicating 60.6% undervaluation), and a risk analysis highlighting low revenue, unprofitability, and insider selling. The report also covers the company's fundamentals, recent news, and price performance, noting its underperformance compared to the US Biotechs industry and the broader US market over the past year.

Original reporting
Published Apr 12, 2026, 8:09 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 12, 2026, 8:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Sera Prognostics (Nasdaq:SERA) - Stock Analysis — source image
Decision brief

The 30-second read

$SERANeutralMed
01

Why it matters

The undervaluation presents a potential opportunity, but fundamental weaknesses and recent underperformance suggest a cautious approach.

02

Market read

While the stock is undervalued, fundamental risks and recent performance issues limit immediate trading enthusiasm. Suitable for risk-tolerant investors.

03

What to watch

Potential upcoming catalysts or news events could alter the outlook; also, macroeconomic factors affecting biotech valuations.

Timing: moderate; upcoming earnings or news could influence short-term movements.

Background

Sera Prognostics specializes in women's health, with a focus on prenatal diagnostics. The company faces challenges due to low revenue and profitability, impacting investor confidence.

Company-level read

Ticker impact

$SERANeutralMedium confidence
Context

Primary focus of the news, given the detailed analysis of Sera Prognostics (SERA).

Expected impact

Potential upward correction towards the analyst target of US$5, representing approximately 60.6% upside, assuming no negative fundamental developments.

Evidence & confidence

The analysis is based on valuation metrics, recent news, and technical performance. The undervaluation suggests potential for gains, but fundamental risks and recent underperformance warrant caution.

Market effects

The company's underperformance may reflect broader challenges in the women's health biotech sector, potentially impacting related stocks.

Limited; as a US-listed biotech, regional effects are minimal unless sector-wide issues emerge.

Low; the company's size and focus limit its influence on global markets.

Counterpoint

The fundamental risks and insider selling may indicate underlying issues that could lead to further decline, cautioning against aggressive positions.

Key entities

  • Sera Prognostics

    A women's health biotech company focusing on prenatal diagnostics.

Related articles

$LMTMedAI 8/10

What is Patriot missile system, why its supplies are down

The article explains the U.S.-made Patriot mobile air defense system and why interceptor missile supplies are down. It cites Raytheon and Lockheed for system details and notes CSIS estimates about 65% of U.S. interceptors were expended Feb to July, leaving under 850. It says the U.S. approved 5,250 interceptors for Gulf states and awarded Lockheed a contract up to $58.6B.

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.